Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

SAB Biotherapeutics (SABS) Total Non-Current Liabilities: 2021-2025

Historic Total Non-Current Liabilities for SAB Biotherapeutics (SABS) over the last 5 years, with Sep 2025 value amounting to $16.0 million.

  • SAB Biotherapeutics' Total Non-Current Liabilities rose 24.83% to $16.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $16.0 million, marking a year-over-year increase of 24.83%. This contributed to the annual value of $11.8 million for FY2024, which is 20.39% down from last year.
  • As of Q3 2025, SAB Biotherapeutics' Total Non-Current Liabilities stood at $16.0 million, which was down 0.87% from $16.1 million recorded in Q2 2025.
  • Over the past 5 years, SAB Biotherapeutics' Total Non-Current Liabilities peaked at $31.9 million during Q4 2021, and registered a low of $4.3 million during Q1 2021.
  • Its 3-year average for Total Non-Current Liabilities is $14.3 million, with a median of $14.9 million in 2023.
  • Per our database at Business Quant, SAB Biotherapeutics' Total Non-Current Liabilities spiked by 466.41% in 2022 and then tumbled by 41.17% in 2023.
  • Over the past 5 years, SAB Biotherapeutics' Total Non-Current Liabilities (Quarterly) stood at $31.9 million in 2021, then crashed by 38.73% to $19.5 million in 2022, then decreased by 23.86% to $14.9 million in 2023, then decreased by 20.39% to $11.8 million in 2024, then increased by 24.83% to $16.0 million in 2025.
  • Its last three reported values are $16.0 million in Q3 2025, $16.1 million for Q2 2025, and $15.4 million during Q1 2025.